542
Views
82
CrossRef citations to date
0
Altmetric
Research Article

QUETIAPINE IMPROVES VISUAL HALLUCINATIONS IN PARKINSON DISEASE BUT NOT THROUGH NORMALIZATION OF SLEEP ARCHITECTURE: RESULTS FROM A DOUBLE-BLIND CLINICAL-POLYSOMNOGRAPHY STUDY

, , , , , , , , & show all
Pages 2196-2205 | Received 04 Jul 2009, Published online: 16 Nov 2009

REFERENCES

  • Arnulf, I., Knofal, E., Merino-Andreu, M., Houeto, J. L., Mesnage, V., Welter, M. L., . (2002). Parkinson's disease and sleepiness: An integral part of PD. Neurology, 58, 1019–1024.
  • Comella, C. L., Tanner, C. M., & Ristanovic, R. K. (1993). Polysomnographic sleep measures in Parkinson's disease patients with treatment-induced hallucinations. Annals of Neurology, 34, 710–714.
  • Fernandez, H. H., Aarsland, D., Fénelon, G., Friedman, J. H., Marsh, L., Tröster, A. I., . (2008). Scales to assess psychosis in Parkinson's disease: Critique and recommendations. Movement Disorders, 23(4), 484–500.
  • Fernandez, H. H., Trieschmann, M. E., Burke, M. A., Jacques, C., & Friedman, J. H. (2003). Long-term quetiapine use for drug-induced psychosis among Parkinsonian patients. Movement Disorders, 18(5), 510–514.
  • Friedman, J. H., & Fernandez, H. H. (2002). Atypical antipsychotics in Parkinson sensitive populations. Journal of Geriatric Psychiatry and Neurology, 15(3), 156–570.
  • Goetz, C. G., & Stebbins, G. T. (1995). Mortality and hallucinations in nursing home patient with advanced Parkinson's disease. Neurology, 45, 669–671.
  • Juri, C., Chana, P., Tapia, J., Kuntsmann, C., & Parrao, T. (2005). Quetiapine for insomnia in Parkinson disease: Results from an open-label trial. Clinical Neuropharmacology, 28, 185–187.
  • Nomura, T., Inoue, Y., Mitani, H., Kawahara, R., Miyake, M., & Nakashima, K. (2003). Visual hallucinations as REM sleep behavior disorders in patients with Parkinson's disease. Movement Disorders, 18, 812–817.
  • Ondo, W. G., Tintner, R., Voung, K. D., Lai, D., & Ringholz, G. (2005). Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease. Movement Disorders, 20(8), 958–963.
  • Pappert, E. J., Goetz, C. G., Niederman, F., Raman, R., & Leurgans, S. (1999). Hallucinations, sleep fragmentation, and altered dream phenomena in Parkinson's Disease. Movement Disorders, 14(1), 117–121.
  • Rabey, J. M., Prokhorov, T., Miniovich, A., Dobronevsky, E., & Klein, C. (2007). The effect of quetiapine in psychotic Parkinson's disease patients: A double-blind labeled study of three months duration. Movement Disorders, 22(3), 313–318.
  • The French Clozapine Parkinson Study Group. (1999). Clozapine in drug-induced psychosis in Parkinson's disease. Lancet, 353(9169), 2041–2042.
  • The Parkinson Study Group. (1999). Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. The New England Journal of Medicine, 340(10), 757–763.
  • Zahodne, L., & Fernandez, H. H. (2008). Pathophysiology and treatment of psychosis in Parkinson's disease: A review. Drugs and Aging, 25(8), 665–682.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.